High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: Possible de novo autoimmune hepatitis?

Gut

Volumn 56, Issue 2, 2007, Pages 237-242

  Berardi, S ^b   Lodato, F ^b   Gramenzi, A ^b   D'Errico, A ^b   Lenzi, M ^b   Bontadini, A ^b   Morelli, M C ^b   Tame M R ^b   Piscaglia, F ^b   Biselli, M ^b   Sama, C ^b   Mazzella, G ^b   Pinna, A D ^b   Grazi, G ^b   Bernardi, M ^b   Andreone, P ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; LYMPHOCYTE ANTIBODY; MITOCHONDRION ANTIBODY; PEGINTERFERON ALPHA2B; PREDNISONE; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE THYROIDITIS; CHOLANGITIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT DYSFUNCTION; HEPATITIS C; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT DISEASE; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

AGED; ALANINE TRANSAMINASE; ANTIBODIES, ANTINUCLEAR; ANTIVIRAL AGENTS; FEMALE; GRAFT REJECTION; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2B; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MITOCHONDRIA; RECURRENCE; RIBAVIRIN; RISK FACTORS; RNA, VIRAL;

EID: 33846990951     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.092064     Document Type: Article

References (27)

1. Kerkar N, Hadzic N, Davies ET, et al. De novo autoimmune hepatitis after liver transplantation. Lancet 1998;351:409-13.
2. Salcedo M, Vaquera J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002;35:349-56.
3. Alvarez F, Berg P, Bianchi F, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
4. Aichele P, Bachmann MF, Hengartner H, et al. Immunopathology or organ-specific autoimmunity as a consequence of virus infection. Immunol Rev 1996;152:21-45.
5. Voehringer D, Blaser C, Grawitz AB, et al. Break of T cell ignorance to a viral antigen in the liver induces hepatitis. J Immunol 2000;165:2415-22.
6. Czaja AJ, Donaldson FT. Genetic susceptibilities for immune expression and liver cell injuriy in autoimmune hepatitis. Immunol Rev 2000;174:250-9.
7. Fainboim L, Velasco VCC, Marcos CY, et al. Protracetd, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB1*1301, a marker for pediatric autoimmune hepatitis. Hepatology 2001;33:1512-17.
8. Czaja AJ. Understanding the pamogenesis of autoimmune hepatitis. Am J Gastroenterol 2001;96:1224-31.
9. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J 1998;12:1255-65.
10. Albert U, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999;341:2068-74.
11. Behar SM, Porcelli SA. Mechanisms of autoimmune disease induction. The role of the immune response to microbial pathogens. Arthritis Rheum 1995;38:458-76.
12. Beschorner WE, Suresch DL, Shinozawa T, et al. Thymic immunopathology after cyclosporin: effect of irradiation and age on medullary involution and recovery. Transplant Proc 1988;20:1072-8.
13. Lotem J, Kama R, Sachs L. Suppression or induction of apoptosis by opposing pathways downstream from calcium-activated calcineurin. Proc Natl Acad Sci USA 1999;96:12016-20.
14. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001;21:225-32.
15. Duelli L, Ferrero B, Oggero A, et al. Thyroid function and autoimmunity during interferon beta-1b treatment: a multicentric prospective study. J Clin Endocrinol Metab 2001;86:3525-32.
16. Garcìa-Buei L, Garcìa-Monzòn C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108: 1770-7.
17. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic hepatitis. Hepatology 1981;1:431-5.
18. Demetrius AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-63.
19. McCaughan GW, Bishop GA. Atherosclerosis of the liver allograft. J Hepatol 1997;27:592-8.
20. Muratori L, Muratori P, Granito A, et al. The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis. Dig Liv Dis 2005;37:108-12.
21. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003;361:1502- 10.
22. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
23. CzaJa AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transplant 2002;8:505-13.
24. Biselli M, Lorenzini S, Gramenzi A, et al. Hepatic artery stenosis in liver transplant patients treated with pegylated interferon alfa-2b and ribavirin. Transplantation 2004;78:953-4.
25. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediate diseases: implications for immunotherapy. Nat Rev Immunol 2002;2:85-95.
26. Oertel M, Sack U, Kohlhaw K, et al. Induction therapy including antithymocyte globuline induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long term study. Transplant Int 2002;15:463-71.
27. Franzke A, Piao W, Lauber J, et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune disease. Blood 2003;102:734-9.